Literature DB >> 1703042

Inhibition of angiogenesis and tumor growth by a synthetic laminin peptide, CDPGYIGSR-NH2.

N Sakamoto1, M Iwahana, N G Tanaka, Y Osada.   

Abstract

A laminin-derived synthetic peptide, Cys-Asp-Pro-Gly-Tyr-Ile-Gly-Ser-Arg-NH2 (CDPGYIGSR-H2), containing an active site for cell binding inhibited both angiogenesis and solid tumor growth. It potently suppressed both embryonic angiogenesis of the chick chorioallantoic membrane and migration of vascular endothelial cells induced by a tumor-conditioned medium but neither the in vitro proliferation of endothelial cells nor that of tumor cells. Additionally, in in vivo tests, CDPGYIGSR-NH2 markedly inhibited both the growth of s.c. solid tumor of Sarcoma 180 and that of Lewis lung carcinoma (3LL) in the lungs. On the contrary, ascitic tumor growth of Sarcoma 180 was not affected by this peptide, even though the same cell source was used. It was concluded that solid tumor growth inhibition by CDPGYIGSR-NH2 was due not a direct effect on cell growth but to antiangiogenic effect mediated by the inhibition of endothelial cell migration.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1703042

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

Review 1.  Mechanisms of tumor angiogenesis and therapeutic implications: angiogenesis inhibitors.

Authors:  H Malonne; I Langer; R Kiss; G Atassi
Journal:  Clin Exp Metastasis       Date:  1999-02       Impact factor: 5.150

2.  Characterization of two monoclonal antibodies directed against the 67 kDa high affinity laminin receptor and application for the study of breast carcinoma progression.

Authors:  S Martignone; R Pellegrini; E Villa; N N Tandon; A Mastroianni; E Tagliabue; S Ménard; M I Colnaghi
Journal:  Clin Exp Metastasis       Date:  1992-11       Impact factor: 5.150

Review 3.  A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction).

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

Review 4.  The preclinical evaluation of angiogenesis inhibitors.

Authors:  M S O'Reilly
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

5.  Phosphorylation mapping of Laminin β1-chain: Kinases in association with active sites.

Authors:  Kleio-Maria Verrou; Panagiota Angeliki Galliou; Maria Papaioannou; Georgios Koliakos
Journal:  J Biosci       Date:  2019-06       Impact factor: 1.826

6.  Identification of haptoglobin as an angiogenic factor in sera from patients with systemic vasculitis.

Authors:  M C Cid; D S Grant; G S Hoffman; R Auerbach; A S Fauci; H K Kleinman
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

7.  A ribonuclease inhibitor expresses anti-angiogenic properties and leads to reduced tumor growth in mice.

Authors:  I J Polakowski; M K Lewis; V R Muthukkaruppan; B Erdman; L Kubai; R Auerbach
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

8.  Control pathways of the 67 kDa laminin binding protein: surface expression and activity of a new ligand binding domain.

Authors:  T H Landowski; S Uthayakumar; J R Starkey
Journal:  Clin Exp Metastasis       Date:  1995-09       Impact factor: 5.150

9.  Differential expression of laminin receptors in human hepatocellular carcinoma.

Authors:  I Ozaki; K Yamamoto; T Mizuta; S Kajihara; N Fukushima; Y Setoguchi; F Morito; T Sakai
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

Review 10.  Basement membrane and the SIKVAV laminin-derived peptide promote tumor growth and metastases.

Authors:  T M Sweeney; M C Kibbey; M Zain; R Fridman; H K Kleinman
Journal:  Cancer Metastasis Rev       Date:  1991-10       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.